## **CKMT2** Monoclonal Antibody

Catalog No: #27124

Package Size: #27124-1 50ul #27124-2 100ul



Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com

| _                |      |     |     |     |
|------------------|------|-----|-----|-----|
|                  | esci | rın | tic | ۱n  |
| $\boldsymbol{L}$ | しつし  | טוו | uv  | , , |


| Product Name          | CKMT2 Monoclonal Antibody   |
|-----------------------|---|
| Host Species          | Mouse   |
| Clonality             | Monoclonal  |
| Clone No.             | 3F4-G5-H5   |
| Isotype               | lgG2b   |
| Purification          | Affinity purified   |
| Applications          | ELISA WB  |
| Species Reactivity    | Hu D Rt Rb Ms P   |
| Immunogen Type        | Recombinant protein   |
| Immunogen Description | Purified recombinant human CKMT2 protein fragments expressed in E.coli.                                 |
| Target Name           | CKMT2   |
| Other Names           | SMTCK   |
| Formulation           | Purified mouse monoclonal in buffer containing 0.1M Tris-Glycine (pH 7.4, 150 mM NaCl) with 0.2% sodium |
|                       | azide, 50%,glycerol   |

## **Application Details**

Predicted MW: 47kd

Western blotting: 1:1000

## **Images**



Western blot detection of CKMT2 in Rat Brain lysates using CKMT2 antibody (1:1000 diluted).
Predicted band size:47KDa.
Observed band size:47KDa

## Background

Reversibly catalyzes the transfer of phosphate between ATP and various phosphogens (e.g. creatine phosphate). Creatine kinase isoenzymes play a central role in energy transduction in tissues with large, fluctuating energy demands, such as skeletal muscle.

| Note: This product is for in vitro research use only and is not intended for use in humans or animals. |  |  |  |  |
|--|--|--|--|--|
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |
|  |  |  |  |  |